Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders
Open accessThe DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 51 of the 105 sources its claims cite were checked for support.
Abstract
Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2). The upper limit of normal determined by the manufacturer is 11.4 ng/mL; however, this boundary has been the subject of debate. According to ECNM and AIM experts, the normal range of baseline tryptase should be 1 to 15 ng/mL. A genetic trait, hereditary alpha tryptasemia, characterized by an increased alpha coding TPSAB1 copy number is associated with a baseline value above 8 ng/mL. Elevated tryptase can also be found in chronic kidney disease, obesity, and hematological neoplasms. A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome. The goal of this review is to demonstrate the (in)significance of tryptase using some clinical vignettes and to provide a practical guide on how to manage and interpret an elevated tryptase level.
Overview
CoChat Summary
TL;DR
This narrative review explains how serum tryptase should be interpreted for suspected mast cell disorders, emphasizing paired acute and baseline sampling and the 20% + 2 consensus formula. It uses seven clinical vignettes to show that elevated baseline tryptase is often due to hereditary alpha-tryptasemia or renal failure, while tryptase >20 ng/mL or a documented acute rise supports systemic mastocytosis or MCAS.
Key findings
- For suspected mast cell activation, acute tryptase should ideally be measured 30–120 min after symptom onset (up to 4 h), paired with baseline tryptase at least 24 h later; the consensus formula is aST ≥ [(1.2 × bST) + 2], i.e., an increase of 20% + 2 ng/mL.
- Baseline tryptase >20 ng/mL is a minor criterion for systemic mastocytosis, and documented mast cell activation by paired tryptase is a required criterion in mast cell activation syndrome; the manufacturer’s upper limit of normal is 11.4 ng/mL, but ECNM/AIM experts state the normal baseline range should be 1–15 ng/mL.
- Elevated baseline tryptase is most commonly caused by hereditary alpha-tryptasemia (91%), followed by chronic renal failure (7%) and hematologic malignancies/mastocytosis (1%); hereditary alpha-tryptasemia involves increased alpha-coding TPSAB1 copy number, is associated with baseline tryptase >8 ng/mL, and is found in up to 6% of the general population.
- In the vignettes, tryptase supported diagnoses such as indolent systemic mastocytosis (aST >200 ng/mL, bST 20 ng/mL), monoclonal MCAS (aST 909 ng/mL, bST 8.3 ng/mL), and hereditary alpha-tryptasemia (bST 19.1 ng/mL with alpha copy number 3 and beta copy number 2).
Methods
- Narrative review with no primary data collection; it synthesizes literature on tryptase biology, diagnostic criteria, and management of suspected mast cell disorders.
- Uses seven clinical vignettes (sections 2.1–2.7) of patients with suspected anaphylaxis or mast cell disorders to illustrate interpretation of acute and baseline tryptase.
- Main analysis is qualitative synthesis; no systematic search, meta-analysis, or formal diagnostic accuracy calculation is reported.
Limitations
- Stated: the clinical relevance of hereditary alpha-tryptasemia is still under debate because not everyone with the trait experiences mediator-related symptoms or anaphylaxis; the link between hereditary alpha-tryptasemia and systemic mastocytosis remains to be elucidated.
- Stated: the consensus formula may miss mast cell activation in some patients, especially food-induced anaphylaxis, where only a 30% tryptase increase may suffice; an aST/bST ratio above 1.685 requires further validation, and more research is needed on α/β-tryptase heterotetramers.
- Evident from the design: this is a narrative review with selected clinical vignettes, not a systematic review or prospective validation study, so the cases are illustrative rather than generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
38 Valid · 1 Not valid · 22 Not checked · 29 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2).”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Partly supportedcites [10] Valent, 2019, Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome, Int. Arch. Allergy Immunol. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes tryptase as a specific marker of severe systemic mast-cell activation, gives a 2–4-hour diagnostic window, and specifies an event-related rise of at least 20% over baseline plus 2 ng/mL. It says tryptase may take up to 24 hours to return to baseline, but does not explicitly prescribe collecting the baseline sample at least 24 hours after the event. The Summary and Future Perspectives also cautions that the formula usually does not capture mild or local activation, a limitation absent from the claim. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [11] Ebo, 2021, Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis, J. Allergy Clin. Immunol. Pract. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome.”
- Also stated in: § 1. Introduction · boosted
“Documented MCA based on paired tryptase samples is also a validated and required criterion in mast cell activation syndrome (MCAS).”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Supportedcites [10] Valent, 2019, Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome, Int. Arch. Allergy Immunol. source
The Introduction (page unavailable) lists an event-related, transient serum tryptase rise of at least 20% above the individual’s baseline plus 2 ng/mL as one of the criteria for diagnosing MCAS. It specifies measurement within 2–4 hours after the reaction. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [11] Ebo, 2021, Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis, J. Allergy Clin. Immunol. Pract. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, it seems to be a disease-modifying trait in anaphylaxis and PMCD [19,20,21].”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [19] Beyens, 2022, Mastocytosis and related entities: A practical roadmap, Acta Clin. Belg. source
- Supportedcites [20] Rijavec, 2023, Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis, Clin. Exp. Allergy source
The Abstract calls HαT a genetic modifier of anaphylaxis. Section 3.3 (page not provided) reports that HαT-associated clonal mast cell disorders appear to have a distinct course and that patients with both HαT and systemic mastocytosis have more severe anaphylaxis. This supports the citing sentence’s hedged description of HαT as a disease-modifying trait. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [21] Carter, 2023, Extrinsic and Intrinsic Modulators of Anaphylaxis, J. Allergy Clin. Immunol. Pract. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome.”
- Also stated in: § 1. Introduction · plain
“If bST is more than 20 ng/mL, a minor criterion for the diagnosis of systemic mastocytosis (SM) is met [12,13,14].”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Could not verifycites [12] Valent, 2022, Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium, J. Allergy Clin. Immunol. Pract. sourceExperimental — accuracy not yet measured
The paper’s diagnostic-criteria section and Table I discuss a tryptase rise of 20% plus 2 ng/mL for mast cell activation syndrome, which is a different criterion. Searches for the 20 ng/mL threshold and minor criteria for systemic mastocytosis found no passage in our copy stating the attributed claim. (LLM, conf=0.72)
- Could not verifycites [13] Valent, 2022, Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022, Int. Arch. Allergy Immunol. sourceExperimental — accuracy not yet measured
The Clinical Manifestations and Laboratory Correlates of MCA section says persistently elevated tryptase may point to occult mastocytosis. Searches for the 20 ng/mL threshold and minor diagnostic criteria found no passage in our copy stating that tryptase >20 ng/mL is a minor criterion for systemic mastocytosis. (LLM, conf=0.72)
- Supportedcites [14] Pardanani, 2023, Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management, Am. J. Hematol. source
Table 4 (section 2.1, Bone marrow histology) lists baseline serum tryptase >20 ng/mL as a minor criterion for systemic mastocytosis. It specifies that elevated tryptase does not count when there is an unrelated myeloid neoplasm and should be adjusted in known hereditary alpha-tryptasemia. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait of an increased copy number of the alpha-coding (of ≥2) TPSAB1-gene [15,16], which may account for elevated serum tryptase in the absence of clonal mast cell disorders.”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
What the sources say
- Supportedcites [15] Lyons, 2018, Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features, Immunol. Allergy Clin. N. Am. source
The Introduction says inherited hereditary alpha tryptasemia is frequently a cause of elevated basal serum tryptase and distinguishes it from elevations due to clonal expansion of mast cells. The Associated clinical features section also discusses elevated tryptase in the absence of clonal mast cell disease. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [16] Lyons, 2016, Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat. Genet. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
40 more claims · 11 with their cited sources checked
Create a free account to see all 90 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“growing knowledge of hereditary alpha-tryptasemia (HαT), a germline condition causing increase in BST with not fully elucidated clinical consequences (4–6).”
From Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
“If bST is more than 20 ng/mL, a minor criterion for the diagnosis of systemic mastocytosis (SM) is met”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 3. Discussion
“A bST ≥ 20 ng/mL is a minor criterion for the diagnosis of SM.”
Citations
Cites
Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents
Sampson, H. A., Mendelson, L., & Rosen, J. P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208063270603 · Cited by 1,609 · cited 1×
“This is especially true for patients with food-induced anaphylaxis [31,32], in which only a 30% increase in tryptase seems to suffice [33].”
BackgroundValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477 · cited 1×
“In acute settings, such as suspected anaphylaxis or MC mediator-related symptoms, an aST should ideally be measured from 30 up to 120 min after the start of symptoms since this will correspond with the peak value [24].”
BackgroundTryptase from human pulmonary mast cells. Purification and characterization
Schwartz, L. B., Lewis, R. A., & Austen, K. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68496-6 · Cited by 419
Lyons, J. J., Yu, X., Hughes, J. D., Le, Q. T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M. P., et al. (2016) · Nature Genetics · doi:10.1038/ng.3696 · Cited by 394
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Costa, J. J., Demetri, G. D., Harrist, T. J., Dvorak, A. M., Hayes, D. F., Merica, E. A., Menchaca, D. M., Gringeri, A. J., Schwartz, L. B., & Galli, S. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2681 · Cited by 268 · cited 1×
“An increase in SCF can induce MC hyperplasia and thus give rise to elevated bST [75].”
BackgroundDevelopment of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263 · cited 1×
“The tryptase assay commercially available from Thermo Fisher ® (Waltham, MA, USA) ImmunoCAP measures all of these isoforms in monomeric and tetrameric form (i.e., total serum tryptase) [9].”
MethodLyons, J. J., Chovanec, J., O’Connell, M. P., Liu, Y., Šelb, J., Zanotti, R., Bai, Y., Kim, J., Le, Q. T., DiMaggio, T., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.06.035 · Cited by 230 · cited 1×
“There is a consensus that H α T is a risk modifier of severe anaphylaxis [21,48–53].”
BackgroundSperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
Greiner, G., Sprinzl, B., Górska, A., Ratzinger, F., Gurbisz, M., Witzeneder, N., Schmetterer, K. G., Gisslinger, B., Uyanik, G., Hadzijusufovic, E., et al. (2021) · Blood · doi:10.1182/blood.2020006157 · Cited by 189
Alvarez-Twose, I., González-de-Olano, D., Sánchez-Muñoz, L., Matito, A., Jara-Acevedo, M., Teodosio, C., García-Montero, A., Morgado, J. M., Orfao, A., & Escribano, L. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000329856 · Cited by 184
Sala-Cunill, A., Cardona, V., Labrador-Horrillo, M., Luengo, O., Esteso, O., Garriga, T., Vicario, M., & Guilarte, M. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000339749 · Cited by 179
Lyons, J. J. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.003 · Cited by 179 · cited 2×
“In some cases, patients with H α T do present with a clinical picture dominated by mediator-related symptoms (i.e., vibratory urticaria, flushing, abdominal cramps, headache, dysautonomia, etc.) [15,16,45].”
BackgroundHuman mast cell tryptase in biology and medicine
Vitte, J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.04.001 · Cited by 152 · cited 1×
“During the degranulation of MCs (e.g., anaphylaxis), the mature tetrameric forms of tryptase are released, resulting in an increase in total tryptase [2].”
BackgroundTryptase genetics and anaphylaxis
Caughey, G. H. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.026 · Cited by 150
Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3
Pallaoro, M., Fejzo, M. S., Shayesteh, L., Blount, J. L., & Caughey, G. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3355 · Cited by 146 · cited 1×
“In humans, five isoforms can be found: α -, β -, γ -, δ -, and ε -tryptase [4–6].”
Valent, P., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Triggiani, M., Lyons, J. J., Oude Elberink, J. N. G., Arock, M., et al. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000501079 · Cited by 146 · cited 3×
“Using the consensus formula, the aST should have an increase of 20% + 2 ng/mL compared with the bST value [10].”
MethodInfluentialLyons, J. J., Sun, G., Stone, K. D., Nelson, C., Wisch, L., O'Brien, M., Jones, N., Lindsley, A., Komarow, H. D., Bai, Y., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.039 · Cited by 136 · cited 1×
“In some cases, patients with H α T do present with a clinical picture dominated by mediator-related symptoms (i.e., vibratory urticaria, flushing, abdominal cramps, headache, dysautonomia, etc.) [15,16,45].”
BackgroundSystemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Pardanani, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26962 · Cited by 132
Le, Q. T., Lyons, J. J., Naranjo, A. N., Olivera, A., Lazarus, R. A., Metcalfe, D. D., Milner, J. D., & Schwartz, L. B. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190701 · Cited by 126 · cited 1×
“One hypothesis is that the pathological potency of H α T is caused by active heterotetrametric α / β -tryptase and that these are more abundant in patients with a higher α / β ratio [42].”
BackgroundZanotti, R., Lombardo, C., Passalacqua, G., Caimmi, C., Bonifacio, M., De Matteis, G., Perbellini, O., Rossini, M., Schena, D., Busa, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.035 · Cited by 123 · cited 1×
“One should be cautious that patients with SM and anaphylaxis seem to have a lower bST in contrast to patients with SM without anaphylaxis [61–65].”
ResultHereditary alpha-tryptasemia: UK prevalence and variability in disease expression
Robey, R. C., Wilcock, A., Bonin, H., Beaman, G., Myers, B., Grattan, C., Briggs, T. A., & Arkwright, P. D. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.05.057 · Cited by 119 · cited 1×
“The clinical relevance of H α T is still under debate since not everyone with this trait experiences mediator-related symptoms or anaphylaxis [17,18].”
BackgroundExpression of α-tryptase and β-tryptase by human basophils
Jogie-Brahim, S., Min, H.-K., Fukuoka, Y., Xia, H.-Z., & Schwartz, L. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.02.032 · Cited by 113
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106 · cited 1×
“It is therefore recommended to use a highly sensitive technique such as an allele-specific oligonucleotide quantitative reverse transcriptase polymerase chain reaction (ASO-qPCR) [66] or digital droplet PCR (ddPCR) [67].”
MethodCarter, M. C., Desai, A., Komarow, H. D., Bai, Y., Clayton, S. T., Clark, A. S., Ruiz-Esteves, K. N., Long, L. M., Cantave, D., Wilson, T. M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.05.036 · Cited by 97
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
Mateja, A., Wang, Q., Chovanec, J., Kim, J., Wilson, K. J., Schwartz, L. B., Glover, S. C., Carter, M. C., Metcalfe, D. D., Brittain, E., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.007 · Cited by 91
Hereditary alpha tryptasemia is not associated with specific clinical phenotypes
Chollet, M. B., & Akin, C. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.06.017 · Cited by 90
Valent, P., Hartmann, K., Bonadonna, P., Gülen, T., Brockow, K., Alvarez-Twose, I., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.05.007 · Cited by 90
Self-citationvan Anrooij, B., van der Veer, E., de Monchy, J. G. R., van der Heide, S., Kluin-Nelemans, J. C., van Voorst Vader, P. C., van Doormaal, J. J., & Oude Elberink, J. N. G. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1578 · Cited by 89
Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis
Gülen, T., Ljung, C., Nilsson, G., & Akin, C. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.02.008 · Cited by 83
Self-citationDigital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis
Greiner, G., Gurbisz, M., Ratzinger, F., Witzeneder, N., Simonitsch-Klupp, I., Mitterbauer-Hohendanner, G., Mayerhofer, M., Müllauer, L., Sperr, W. R., Valent, P., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.277897 · Cited by 83
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
Self-citationThe presence of mast cell clonality in patients with unexplained anaphylaxis
Gülen, T., Hägglund, H., Sander, B., Dahlén, B., & Nilsson, G. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12369 · Cited by 82
Self-citationVitte, J., Sabato, V., Tacquard, C., Garvey, L. H., Michel, M., Mertes, P.-M., Ebo, D. G., Schwartz, L. B., & Castells, M. C. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.011 · Cited by 79 · cited 1×
“Generally, the severity and magnitude of hypotension in anaphylaxis correlate with the height of tryptase [29,30].”
BackgroundSelf-citationGülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75
Self-citationBorer‐Reinhold, M., Haeberli, G., Bitzenhofer, M., Jandus, P., Hausmann, O., Fricker, M., Helbling, A., & Müller, U. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03848.x · Cited by 73
Sabato, V., Chovanec, J., Faber, M., Milner, J. D., Ebo, D., & Lyons, J. J. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0506-y · Cited by 73
Self-citationValent, P., Hartmann, K., Schwaab, J., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.007 · Cited by 72
Dua, S., Dowey, J., Foley, L., Islam, S., King, Y., Ewan, P., & Clark, A. T. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.01.006 · Cited by 67 · cited 1×
“This is especially true for patients with food-induced anaphylaxis [31,32], in which only a 30% increase in tryptase seems to suffice [33].”
BackgroundSerum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease
Sirvent, A. E., González, C., Enríquez, R., Fernández, J., Millán, I., Barber, X., & Amorós, F. (2010) · Journal of Nephrology · doi:10.1093/joneph/23.3.282 · Cited by 66 · cited 1×
“Non-MC disorders can give rise to bST, such as impaired renal function [73].”
BackgroundŠelb, J., Rijavec, M., Eržen, R., Zidarn, M., Kopač, P., Škerget, M., Bajrović, N., Luzar, A. D., Park, Y. H., Liu, Y., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.02.043 · Cited by 65
Clinical relevance of inherited genetic differences in human tryptases
Glover, S. C., Carter, M. C., Korošec, P., Bonadonna, P., Schwartz, L. B., Milner, J. D., Caughey, G. H., Metcalfe, D. D., & Lyons, J. J. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2021.08.009 · Cited by 64
Chovanec, J., Tunc, I., Hughes, J., Halstead, J., Mateja, A., Liu, Y., O’Connell, M. P., Kim, J., Park, Y. H., Wang, Q., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007936 · Cited by 62
Self-citationWong, G. W., Yasuda, S., Madhusudhan, M. S., Li, L., Yang, Y., Krilis, S. A., Šali, A., & Stevens, R. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108677200 · Cited by 61
Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022
Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524532 · Cited by 55
Boehm, T., Reiter, B., Ristl, R., Petroczi, K., Sperr, W., Stimpfl, T., Valent, P., & Jilma, B. (2019) · Allergy · doi:10.1111/all.13663 · Cited by 53 · cited 1×
“Additionally, diamine oxidase has been shown to significantly increase during anaphylaxis and has a longer half-life compared with tryptase, making this an interesting marker for further evaluation [88].”
BackgroundFamilial hypertryptasemia with associated mast cell activation syndrome
Sabato, V., Van De Vijver, E., Hagendorens, M., Vrelust, I., Reyniers, E., Fransen, E., Bridts, C., De Clerck, L., Mortier, G., Valent, P., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.06.007 · Cited by 52
Inherited and acquired determinants of serum tryptase levels in humans
Lyons, J. J. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2021.06.019 · Cited by 52 · cited 4×
“[8,19].”
BackgroundInfluentialSprinzl, B., Greiner, G., Uyanik, G., Arock, M., Haferlach, T., Sperr, W. R., Valent, P., & Hoermann, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052458 · Cited by 51 · cited 1×
“However, only α - and β -tryptase are clinically relevant and are the most abundant [7].”
BackgroundAnaphylaxis and Mast Cell Disorders
Gülen, T., & Akin, C. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.09.007 · Cited by 51
Self-citationDoctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction
Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.11.045 · Cited by 47 · cited 1×
“For a complete differential diagnosis of mediator-related symptoms [85] or management of these symptoms [86], the reader is referred elsewhere.”
BackgroundElevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System
Waters, A. M., Park, H. J., Weskamp, A. L., Mateja, A., Kachur, M. E., Lyons, J. J., Rosen, B. J., & Boggs, N. A. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.12.031 · Cited by 46
Giannetti, M. P., Akin, C., Hufdhi, R., Hamilton, M. J., Weller, E., van Anrooij, B., Lyons, J. J., Hornick, J. L., Pinkus, G., Castells, M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.017 · Cited by 43 · cited 1×
“Some patients might meet the criteria for MCAS [46,47].”
BackgroundGonzález‐de‐Olano, D., Navarro‐Navarro, P., Muñoz‐González, J. I., Sánchez‐Muñoz, L., Henriques, A., de‐Andrés‐Martín, A., Peralta‐Arjonilla, D., Mayado, A., Jara‐Acevedo, M., García‐Montero, A. C., et al. (2024) · Allergy · doi:10.1111/all.15911 · Cited by 38
Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis
Kačar, M., Rijavec, M., Šelb, J., & Korošec, P. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14264 · Cited by 37
Elevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review
Lee, A. Y. S. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000506199 · Cited by 36 · cited 1×
“Moreover, obesity can be a cause of elevated bST [77], as well as helminthic infections, hematological malignancies, cardiovascular disease, (nummular) eczema, or rare genetic mutations (e.g., GATA2 or PLAID) [8,78,79].”
BackgroundSevere food allergy reactions are associated with α-tryptase
Lang, A., Kubala, S., Grieco, M. C., Mateja, A., Pongracic, J., Liu, Y., Frischmeyer-Guerrerio, P. A., Kumar, R., & Lyons, J. J. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.014 · Cited by 36 · cited 1×
“There is a consensus that H α T is a risk modifier of severe anaphylaxis [21,48–53].”
BackgroundExposure to tobacco-derived materials induces overproduction of secreted proteinases in mast cells
Small-Howard, A., & Turner, H. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.09.003 · Cited by 32
Egner, W., Sargur, R., Shrimpton, A., York, M., & Green, K. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12785 · Cited by 31 · cited 1×
“Different approaches have been proposed such as a delta tryptase > 3 ng/mL or a rise of 35% in tryptase [27,28].”
Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome
Butterfield, J. H. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.02.017 · Cited by 30
Butterfield, J. H. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.008 · Cited by 27
Pyatilova, P., Akin, C., Alvarez-Twose, I., Arock, M., Bonadonna, P., Brockow, K., Butterfield, J. H., Broesby-Olsen, S., Carter, M. C., Castells, M., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.05.037 · Cited by 27
Self-citationEbo, D. G., De Puysseleyr, L. P., Van Gasse, A. L., Elst, J., Poorten, M.-L. V. D., Faber, M. A., Mertens, C., Van Houdt, M., Hagendorens, M. M., Sermeus, L., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.050 · Cited by 26 · cited 2×
“In perioperative anaphylaxis, the consensus formula showed the best sensitivity and specificity [11].”
BackgroundMethodInfluentialDifferential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia
Giannetti, M. P., Godwin, G., Weller, E., Butterfield, J. H., & Castells, M. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.025 · Cited by 25 · cited 2×
“However, one should keep in mind that these metabolites have yet to be validated [34], although an increase of 1.3 in leukotriene E4, 2,3-dinor-11b-prostaglandinF2a, and n-methylhistamine has been proposed as a possible sign of MCA [87].”
BackgroundInfluential(2023) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2023.07.001 · Cited by 25
Self-citationElst, J., van der Poorten, M. M., Van Gasse, A. L., Mertens, C., Hagendorens, M. M., Ebo, D. G., & Sabato, V. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14110 · Cited by 23 · cited 1×
“Note that even when MCA is depicted, no conclusion can be drawn about the mechanism (IgE-mediated or non-IgE-mediated) responsible for MC degranulation [38,39].”
BackgroundSelf-citationTryptase reference ranges are age-dependent in a large population-based cohort
Slot, M. C., Claessen, L. H. J., Bons, J. A. P., Menheere, P. P. C. A., Nieuwhof, C. M. G., & de Boer, D. (2022) · Allergy · doi:10.1111/all.15369 · Cited by 22 · cited 1×
“Tryptase also tends to rise with age [76].”
BackgroundTryptase is not cleared by the kidneys into the urine
Simon, M. R., Jan, M., Yee, J., Nori, U. S., Hu, J., Akin, C., & Schwartz, L. B. (2010) · International Archives of Allergy and Immunology · doi:10.1159/000260080 · Cited by 21 · cited 1×
“Probably, this is due to an elevated SCF since tryptase is not cleared by kidneys [74].”
BackgroundNew Biomarkers in Anaphylaxis (Beyond Tryptase)
Galvan-Blasco, P., Gil-Serrano, J., & Sala-Cunill, A. (2022) · Current Treatment Options in Allergy · doi:10.1007/s40521-022-00326-1 · Cited by 19
Disease Spectrum of Anaphylaxis Disorders
González de Olano, D., Cain, W. V., Bernstein, J. A., & Akin, C. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.05.012 · Cited by 19
Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects
Vos, B. J. P. R., van der Veer, E., van Voorst Vader, P. C., Mulder, A. B., van der Heide, S., Arends, S., Kluin-Nelemans, J. C., de Monchy, J. G. R., van Doormaal, J. J., & Oude Elberink, J. N. G. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.047 · Cited by 17 · cited 1×
“Moreover, obesity can be a cause of elevated bST [77], as well as helminthic infections, hematological malignancies, cardiovascular disease, (nummular) eczema, or rare genetic mutations (e.g., GATA2 or PLAID) [8,78,79].”
BackgroundAnaphylaxis: Mediators, Biomarkers, and Microenvironments
Fernandez-Bravo, S., Palacio-Garcia, L., Requena-Robledo, N., Yuste-Montalvo, A., Nuñez-Borque, E., & Esteban, V (2022) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0854 · Cited by 17
Extrinsic and Intrinsic Modulators of Anaphylaxis
Carter, M. C., Park, J., Vadas, P., & Worm, M. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.05.015 · Cited by 17 · cited 2×
“However, it seems to be a disease-modifying trait in anaphylaxis and PMCD [19–21].”
BackgroundDölle-Bierke, S., Siebenhaar, F., Burmeister, T., & Worm, M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.07.037 · Cited by 16
Elevated levels of tryptase in children with nummular eczema
Lange, L., Rietschel, E., Hunzelmann, N., & Hartmann, K. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01731.x · Cited by 15 · cited 1×
“Moreover, obesity can be a cause of elevated bST [77], as well as helminthic infections, hematological malignancies, cardiovascular disease, (nummular) eczema, or rare genetic mutations (e.g., GATA2 or PLAID) [8,78,79].”
BackgroundFalse-elevated serum tryptase assay result caused by heterophilic antibodies
van Toorenenbergen, A. W., van Daele, P. L. A., & Boonstra, J. G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.07.023 · Cited by 15
Basal serum tryptase: A critical reconsideration of reference values
Francois, F., Mauff, B. L., Waeckel, L., de Chaisemartin, L., Tabary, T., Dumontet, E., Lecron, J. C., Delamare, B., Boumediene, A., Chauvineau‐Grenier, A., et al. (2023) · Allergy · doi:10.1111/all.15790 · Cited by 15 · cited 1×
“The majority are healthy individuals and will not develop any MC-related conditions [41].”
BackgroundNantanee, R., Suratannon, N., & Chatchatee, P. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000518319 · Cited by 14 · cited 1×
“This is especially true for patients with food-induced anaphylaxis [31,32], in which only a 30% increase in tryptase seems to suffice [33].”
BackgroundManagement of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis
Gülen, T. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.04.010 · Cited by 14 · cited 1×
“For a complete differential diagnosis of mediator-related symptoms [85] or management of these symptoms [86], the reader is referred elsewhere.”
BackgroundSelf-citationPersistent tryptase elevation in a patient with Gaucher disease
Schussler, E., Yang, A., Lyons, J. J., Milner, J. D., & Wang, J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.039 · Cited by 13 · cited 1×
“Also, a case of a patient with Gaucher Disease type 1, a lysosomal storage disorder, was reported to have an elevated tryptase level (up to 80 ng/mL) that improved upon initiation of enzyme replacement therapy [82].”
BackgroundDiagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood
De Puysseleyr, L. P., Ebo, D. G., Elst, J., Faber, M. A., Poorten, M.-L. V. D., Van Gasse, A. L., Bridts, C. H., Mertens, C., Van Houdt, M., Hagendorens, M. M., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.04.062 · Cited by 13
Self-citationMastocytosis and related entities: A practical roadmap
Beyens, M., Elst, J., van der Poorten, M.-L., Van Gasse, A., Toscano, A., Verlinden, A., Vermeulen, K., Maes, M.-B., Oude Elberink, J. N. G. H., Ebo, D., et al. (2023) · Acta Clinica Belgica · doi:10.1080/17843286.2022.2137631 · Cited by 13 · cited 2×
“[8,19].”
BackgroundDefining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: Are we there yet?
Couto, M. L., Silva, M., Barbosa, M. J., Ferreira, F., Fragoso, A. S., & Azenha Rama, T. (2023) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.288 · Cited by 10
Serum concentrations of mast cell tryptase are reduced in heavy drinkers
Beceiro, C., Campos, J., Valcarcel, M.-A., Fenger, R. V., Lojo, S., Linneberg, A., Vidal, C., & Gonzalez-Quintela, A. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12682 · Cited by 9 · cited 1×
“Even alcohol consumption [80] or tobacco smoking [81] can decrease or elevate bST, respectively.”
BackgroundSerum Tryptase Cannot Differentiate Vancomycin-Induced Anaphylaxis From Red Man Syndrome
Noguchi, S., Takekawa, D., Saito, J., Hashiba, E., & Hirota, K. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00707-3 · Cited by 9 · cited 1×
“Note that even when MCA is depicted, no conclusion can be drawn about the mechanism (IgE-mediated or non-IgE-mediated) responsible for MC degranulation [38,39].”
BackgroundDetection of clonal mast cell disease in wasp venom allergic patients with normal tryptase
Onnes, M. C., Alheraky, A., Nawijn, M. C., Sluijter, T. E., Mulder, A. B., Arends, S., & Oude Elberink, H. N. G. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12174 · Cited by 8 · cited 1×
“Importantly, even with a highly sensitive test, a negative result for the KIT D816V mutation in peripheral blood would not exclude underlying PMCD, since this has a low negative predictive value [68,69].”
BackgroundVitte, J., Gonzalez, C., Klingebiel, C., & Michel, M. (2022) · Revue française d'allergologie · doi:10.1016/j.reval.2022.02.218 · Cited by 5 · cited 1×
“Paired analysis of both values allows one to determine if MCA had taken place and should always be checked [26].”
BackgroundMediators of anaphylactic reactions: Tryptase and histamine stability in whole blood
Serrier, J., Khoy, K., Petit, G., Parienti, J., Laroche, D., Mariotte, D., & Le Mauff, B. (2021) · Allergy · doi:10.1111/all.14663 · Cited by 4 · cited 1×
“The sample can always be stored or shipped for analysis afterward since tryptase is rather stable [25].”
Background
Cited by
Diagnostic Utility of Biomarkers in Anaphylaxis: A Systematic Review and Meta-Analysis
Khalaf, R., Prosty, C. J., Davalan, W., Abrams, E. M., Kaouache, M., & Ben‐Shoshan, M. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.04.008 · Cited by 24
Role of Mast Cells and Their Mediators in Chronic Kidney Diseases
Tziastoudi, M., Cholevas, C., Eleftheriadis, T., Stefanidis, I., & Theoharides, T. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209981 · Cited by 8
“Its clinical utility is particularly evident when acute (within 4 h of an event) and baseline (at least 24 h after an event) serum levels are compared, following the consensus formula of a 20% + 2 ng/mL increase [98,99].”
Ma, Q., Hai, Y., Duan, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550694 · Cited by 5
Wang, B., Bai, H., Yuan, P., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109351 · Cited by 4
Crupi, F., Caroprese, J., & Mannelli, F. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1592001 · Cited by 2
Metadata
- Authors
- Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V.
- Affiliations
- University of Antwerp (BE)
- Karolinska University Hospital (SE)
- Corresponding author
- Ebo, Didier
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2023-12-14
- Volume
- 13
- Issue
- 24
- Pages
- 3662
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC10742504
- OpenAlex
- W4389737509
- Cited by
- 22
- References
- 91
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 3
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (1800614N, 1804518N)
- Konsul T.H.C. Bergh Foundation, Sweden (1800614N, 1804518N)
- Swedish Society of Medicine, Sweden (1800614N, 1804518N)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- tryptase, mast cell activation, mast cell degranulation, mast cell disease, systemic mastocytosis, mast cell activation syndrome, hereditary alpha-tryptasemia, TPSAB1, upper limit of normal, chronic kidney disease, obesity, hematologic malignancies, diagnostic criteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.